Overview
Cardiovascular disease (CVD) encompasses atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), hypertension, and related thrombotic events. The conventional view treats CVD as a lipid-centric or hemodynamic disorder. The microbiome signature framework reveals CVD as an ecological disease driven by dysbiosis that creates three self-reinforcing pathways: (1) TMAO-mediated atherosclerotic plaque formation, (2) metal-dependent bacterial overgrowth, and (3) loss of cardioprotective butyrate-producing bacteria.
CVD exhibits bidirectional causality with the microbiome — dysbiosis drives CVD risk, but CVD itself further worsens dysbiosis through altered intestinal permeability, changed oxygen gradients, and shifted nutrient availability. The oral microbiome adds an additional layer: periodontal dysbiosis seeds pathogens into systemic circulation and triggers chronic inflammation that compounds gut-driven atherosclerosis.
This signature integrates data from 64 peer-reviewed sources on CVD-microbiome interactions, spanning landmark metagenomics studies (Jie 2017), metabolomic profiling (MetaCardis cohort, Fromentin 2022), bidirectional Mendelian randomization studies (Li 2023 hypertension, Luo 2022 heart failure), and comprehensive oral-CVD reviews (Tonelli 2023, Foroughi 2026). The signature is platform: both because WikiBiome readers need to understand the metallomic and taxonomic landscape driving CVD, while Cureva practitioners need the full 5-layer reasoning for intervention design.
Metallomic Signature
The metallomic signature in CVD is characterized by elevated nickel, lead, cadmium, and iron, with depleted selenium and glutathione liu 2025 cardiometabolic nickel, jie 2017 gut microbiome acvd, paeslack 2022 tryptophan metabolites vascular inflammation cvd.
Nickel
Nickel elevation in CVD patients is robust liu 2025 cardiometabolic nickel. NHANES 2017-2018 cross-sectional analysis (n=2702) found elevated urinary nickel (UNi) in CVD patients with an inverted L-shaped dose-response relationship. Early clinical observations documented endogenous nickel release post-myocardial infarction, suggesting that cardiac tissue damage itself liberates nickel, which may further exacerbate cardiac contractility inhibition and oxidative stress.
Metal interaction studies show plasma nickel positively correlated with zinc, vanadium, and chromium but negatively correlated with copper, indicating dysregulated metal homeostasis in CVD. Experimental evidence in Swiss mice fed 1,100-1,600 ppm dietary nickel showed reduced cardiac and renal enzyme activity and dose-dependent inhibition of cardiac contractility liu 2025 cardiometabolic nickel.
Lead and Cadmium
These metals drive mis-metallation events (Primitive 3). They enter cells via calcium channels and displace correct metal cofactors. The combination of lead and cadmium produces synergistic oxidative stress beyond either metal alone. Their presence in the GI microenvironment selects for metal-tolerant taxa while eliminating metal-sensitive commensals, contributing to the shift toward Enterobacteriaceae dominance jie 2017 gut microbiome acvd.
Iron Dysregulation
Elevated iron in CVD creates a *selective pressure favoring siderophore-dependent Enterobacteriaceae** like E. coli and Bacteroides jie 2017 gut microbiome acvd. The iron elevation may reflect both environmental exposure and functional anemia (elevated hepcidin) as a host defense mechanism against pathogenic iron-scavenging bacteria. However, in the CVD context, the iron-enriched environment favors pathogenic taxa while depleting butyrate-producing Roseburia and Faecalibacterium*, which lack robust siderophore systems chambers 2018 scfa metabolic cardiovascular health.
Selenium Depletion
Selenium is a cofactor for selenoproteins including glutathione peroxidase (GPx), the primary antioxidant defense against TMAO-induced and metal-induced ROS. Its depletion impairs the host's ability to counteract oxidative damage from dysbiotic TMAO producers and metal-dependent pathogens paeslack 2022 tryptophan metabolites vascular inflammation cvd.
Glutathione Depletion
Glutathione is the only small-molecule metal chelator capable of binding cadmium and lead. Its depletion in CVD represents a critical loss of detoxification capacity, permitting these toxic metals to accumulate and drive further dysbiosis.
Environmental Exposures
Sources of the metal burden include:
| Exposure | Metals Contributed | Relevance to CVD |
|----------|-------------------|-----------------|
| Smoking | Cd, Pb, Ni | Directly damages endothelium; promotes atherosclerosis |
| Occupational | Ni (metal workers), Pb (smelting) | Occupational nickel exposure linked to MetS and T2DM |
| Stainless steel cookware | Ni, Cr, Fe | Cumulative dietary exposure |
| Dietary (largest contributor) | Fe, Zn, Ni, Cd, Pb | Red meat (Fe, Cd), grains (Cd), leafy greens (Pb, Ni) |
| Water supply | Pb, Cd | EPA enforcement gaps; chronic low-level exposure |
| Supplements | Fe, Zn | Over-supplementation in response to low serum iron (ignoring functional anemia) |
The dietary iron content in red meat is particularly relevant because it drives both siderophore-dependent Enterobacteriaceae overgrowth AND promotes heme-iron absorption, creating dual mechanisms of CVD risk jie 2017 gut microbiome acvd.
Nutritional Immunity Response
The host is actively withholding metals from pathogens, not failing nutritionally herrema 2020 microbiome cardiovascular disease ascvd, chambers 2018 scfa metabolic cardiovascular health:
| Factor | Status | Function |
|--------|--------|----------|
| Hepcidin | Elevated | Blocks iron absorption into bloodstream; creates functional anemia; signals CVD is a defended state |
| Transferrin | Elevated | Chelates iron; prevents siderophore-dependent pathogens from acquiring iron locally |
| Lipocalin 2 | Elevated | Binds siderophores (enterobactin, yersiniabactin); blocks iron acquisition |
| Calprotectin | Elevated | Chelates Zn, Mn, Fe; pro-inflammatory signal from activated neutrophils |
| LPS (Lipopolysaccharide) | Elevated (systemic) | Bacterial cell wall component breaching gut barrier → endotoxemia |
| Butyrate | Depleted | Lost due to Roseburia, Faecalibacterium depletion; no longer maintaining gut barrier |
| Glutathione | Depleted | Only defense against Cd/Pb; depletion allows toxic metals to accumulate |
The low serum iron in CVD is NOT a nutritional iron deficiency — it is a host defense response. Supplementing iron feeds the siderophore-dependent Enterobacteriaceae that produce TMAO, directly counteracting the host's defensive effort (Primitive 2: Nutritional Immunity as Interpretive Constraint).
Mis-metallation Events
Cadmium and lead both enter cells via calcium channels, displacing correct cofactors like zinc or magnesium in metalloenzymes (Primitive 3). In the CVD context:
1. Lead displacement of zinc — impairs zinc-dependent enzymes in endothelial cells and platelets, increasing thrombotic risk
2. Cadmium displacement of zinc — impairs zinc-dependent transcription factors in cardiomyocytes, reducing antioxidant gene expression
3. Nickel capture of iron-sulfur clusters — can inhibit complex I and III of the mitochondrial electron transport chain in cardiomyocytes, contributing to diastolic dysfunction and heart failure
These mis-metallation events compound metal-driven dysbiosis by directly damaging tissue defense systems at the cellular level.
Taxonomic Analysis
Enriched Taxa — The TMAO-Producing and LPS-Generating Consortium
The hallmark of CVD dysbiosis is *massive enrichment of Enterobacteriaceae family species, particularly E. coli and Klebsiella, alongside elevated Streptococcus spp. jie 2017 gut microbiome acvd. This consortium is unified by three pathogenic functions: TMAO production, LPS synthesis, and iron piracy.
#### Enterobacteriaceae (specifically E. coli)
Metal dependencies: Fe, Ni, Zn, Mn
Key enzymes: TMA lyase (CutC/D), siderophores (enterobactin, yersiniabactin), LPS biosynthesis, zinc metalloproteases, beta-glucuronidase
Role: The primary TMAO producer in CVD. Encodes TMA lyase enzymes (CutC/D and CntA/B) that metabolize dietary choline and carnitine to trimethylamine (TMA), which is absorbed into portal circulation and hepatically oxidized to TMAO by FMO3 jie 2017 gut microbiome acvd, zhen 2023 tmao cardiovascular diseases review.
TMAO acts as a pro-atherosclerotic metabolite by:
- Inhibiting reverse cholesterol transport (RCT) via downregulation of ABCG5/G8
- Upregulating CD36 and scavenger receptor A1 in macrophages → foam cell formation
- Activating NF-kB pathway → pro-inflammatory cytokine release (TNF-alpha, IL-6)
- Generating ROS via SIRT3-SOD2 pathway
- Activating NLRP3 inflammasome via TXNIP
- Accelerating myocardial hypertrophy via TGF-beta1/Smad3
- Enhancing platelet hyperreactivity → thrombotic risk
E. coli additionally produces LPS (lipopolysaccharide), which translocates through the disrupted gut barrier (via butyrate loss) and activates TLR4 on endothelial cells and macrophages, driving systemic inflammation herrema 2020 microbiome cardiovascular disease ascvd.
#### Streptococcus spp.
Metal dependencies: Fe, Zn, Ni
Key enzymes: TMAO lyase, beta-glucuronidase, hyaluronic acid capsule, M protein (Group A), adhesin B (viridans group)
Role in gut: Enriched in CVD gut microbiome; TMAO-producer. Encoded in the metagenomic classifiers that distinguish ACVD patients from healthy controls with AUC 0.86 jie 2017 gut microbiome acvd.
Role in oral cavity: Streptococcus spp., particularly viridans group streptococci (VGS), colonize the periodontal pocket in periodontitis tonelli 2023 oral microbiome cvd pathophysiology, foroughi 2026 periodontal biomarkers cvd. VGS express:
- Adhesin B — promotes platelet aggregation → bacteremia and infective endocarditis risk
- Heat-shock protein 60 (HSP60) — triggers molecular mimicry against host endothelial HSPs, driving autoimmune-like vascular injury
- M protein — (in Group A Strep) cross-reactive with cardiac myosin, triggering autoimmune heart damage in rheumatic heart disease
Oral VGS bacteremia seeding atherosclerotic plaques is confirmed by bacterial DNA recovery from plaques foroughi 2026 periodontal biomarkers cvd.
#### Bacteroides fragilis
Metal dependencies: Fe, Zn
Key enzymes: Fragilysin (BFT, Zn-dependent toxin), beta-glucuronidase, hydrogenase, siderophores
Role: Strict anaerobe — indicator of local hypoxia. Produces fragilisin (BFT), a zinc-dependent metalloproteolytic toxin that disrupts intestinal tight junctions (destroys claudins and occludin), increasing permeability and enabling translocation of intact bacterial cells and LPS herrema 2020 microbiome cardiovascular disease ascvd.
#### Porphyromonas gingivalis
Metal dependencies: Fe, Zn, Ni
Key enzymes: Gingipains (cysteine proteases), LPS, HSP60, hemin/iron acquisition systems
Role in periodontitis: The keystone periodontal pathogen foroughi 2026 periodontal biomarkers cvd. Expressed gingipains degrade host proteins and matrix metalloproteinases, creating the periodontal pocket. Produces LPS and HSP60 (molecular mimicry target). When periodontal disease is active, P. gingivalis* cells and LPS breach the inflamed periodontal vasculature and enter systemic circulation, inoculating atherosclerotic plaques and triggering endothelial dysfunction tonelli 2023 oral microbiome cvd pathophysiology.
| Taxon | Metal Dependencies | Key Enzymes | Pathogenic Role |
|-------|-------------------|-------------|-----------------|
| enterobacteriaceae (E. coli) | Fe, Ni, Zn | TMA lyase (CutC/D), siderophores, LPS biosynthesis | Primary TMAO + LPS producer; iron piracy |
| streptococcus | Fe, Zn, Ni | TMAO lyase, beta-glucuronidase, HSP60 (oral), adhesin B | Gut TMAO producer; oral bacteremia, molecular mimicry |
| bacteroides fragilis | Fe, Zn | Fragilysin (BFT), beta-glucuronidase, hydrogenase | Tight junction disruption → translocation |
| porphyromonas gingivalis | Fe, Zn, Ni | Gingipains, LPS, HSP60 | Periodontal pathogen; bacteremia; molecular mimicry |
Depleted Taxa — Loss of Cardioprotective Functions
The CVD microbiome is characterized by severe depletion of SCFA-producing bacteria fromentin 2022 microbiome metabolome cardiometabolic spectrum, chambers 2018 scfa metabolic cardiovascular health:
#### Roseburia spp.
Function: Primary butyrate producer in the colon. Butyrate is the major colonocyte fuel and acts on Olfr78/FFAR3 receptors to regulate:
- Renin production → systemic blood pressure control
- Tight junction protein expression → gut barrier integrity
- PYY and GLP-1 release → appetite and glucose homeostasis
Why lost: Butyrate-producing Roseburia require:
1. Anaerobic environment (readily available)
2. Fiber substrate fermentation (adequate if diet is high-fiber, but impaired by CVD-associated dietary changes)
3. Robust metal defense systems to survive iron-rich, pro-inflammatory environment — Roseburia lacks the siderophore systems and efflux pumps necessary to outcompete Enterobacteriaceae in an iron-enriched niche
The loss of Roseburia is causal for CVD risk via the SCFA-BP regulation pathway (Primitive 9: Oxygen State as Ecological Determinant) — the transition from butyrate-dominated to TMAO-dominated ecology directly impairs BP control.
#### Faecalibacterium prausnitzii
Function: Butyrate producer via 4-hydroxyphenylacetate pathway; produces IL-10 (anti-inflammatory cytokine) that suppresses pro-inflammatory NF-kB signaling
Why lost: Like Roseburia, lacks metal defense systems to survive metal-enriched, endotoxemic CVD environment. Cross-disease comparisons show F. prausnitzii depleted in ACVD, obesity, T2D, and liver cirrhosis — a signature of metabolic dysbiosis.
#### Lachnospiraceae Family
Function: SCFA producers (butyrate, propionate, acetate); support colonocyte health via short-chain carboxylic acids
Why lost: Lack robust efflux pumps for metal tolerance; depleted in metal-enriched, pro-inflammatory environment
#### Allisonella spp.
Function: Protective against hypertension li 2023 gut microbiome hypertension bidirectional mr; mechanistic pathway involves SCFA production
Why lost: Sensitive to metal enrichment and dysbiosis-driven ecological shifts
#### Clostridium spp. (including C. innocuum)
Function: Producers of indole metabolites — indole-3-propionic acid (IPA), indole-3-acetic acid (IAA), indole-3-lactic acid (ILA). These indoles activate the aryl hydrocarbon receptor (AhR) in intestinal epithelial cells and immune cells:
- IPA: Anti-atherosclerotic; protective against vascular inflammation despite raising BP (net protective effect)
- IAA and ILA: Promote IL-10 and IL-22 production → anti-inflammatory, barrier-protective immune response
Why lost: Require stable anaerobic conditions; depleted by oxygen influx from dysbiotic changes and dysregulated intestinal motility in CVD
| Taxon | Normal Function | Why Lost | CVD Consequence |
|-------|----------------|----------|-----------------|
| roseburia | Butyrate production; BP regulation via Olfr78/FFAR3 | Lacks metal defense systems | Hypertension via lost SCFA signaling |
| faecalibacterium prausnitzii | Butyrate + IL-10 production; anti-inflammatory | Metal intolerant | Systemic inflammation; mucosal permeability increase |
| lachnospiraceae | SCFA production; colonocyte nutrition | Metal intolerant | Loss of gut barrier maintenance |
| allisonella | Hypertension-protective SCFA pathway | Dysbiosis-sensitive | Uncontrolled hypertension |
| clostridium | Indole metabolite production (IPA, IAA); AhR activation | Oxygen shift from dysbiosis | Loss of protective vascular anti-inflammatory signaling |
Virulence Enzymes and Features
The taxa that persist in CVD express a consistent set of metal-dependent virulence enzymes (Primitive 4: Microbial Metal Dependencies as Achilles' Heels):
| Enzyme | Metal Cofactor | Function | Taxa Expressing | CVD Consequence |
|--------|---------------|----------|-----------------|-----------------|
| TMA lyase (CutC/D) | Fe, Ni | Metabolizes choline → TMA → TMAO | E. coli, Enterobacteriaceae | Atherosclerotic plaque formation, foam cells, platelet hyperreactivity |
| Lipopolysaccharide (LPS) biosynthesis | Zn, Fe, Mn | Gram-negative outer membrane component | E. coli, Streptococcus, B. fragilis, P. gingivalis | Endotoxemia; TLR4 activation; systemic inflammation; endothelial dysfunction |
| Siderophores (enterobactin, yersiniabactin) | Fe | Competitive iron acquisition from host transferrin/lactoferrin | E. coli, Enterobacteriaceae | Functional anemia; competitive exclusion of siderophore-lacking commensals |
| Fragilysin (BFT, Zn-dependent) | Zn | Metalloproteolytic toxin; cleaves claudins, occludin | B. fragilis | Tight junction disruption; intestinal permeability; LPS translocation |
| Gingipains (cysteine proteases) | Zn, Fe | Proteolysis of host proteins; biofilm formation | P. gingivalis | Periodontal inflammation; bacteremia; molecular mimicry via HSP60 |
| Heat-shock protein 60 (HSP60) | — | Molecular mimicry target; cross-reactive with host endothelial HSP60 | Streptococcus, P. gingivalis | Autoimmune vascular injury; atherosclerosis acceleration |
| Beta-glucuronidase | — | Deconjugates estrogen glucuronides; increases recirculation | E. coli, Streptococcus, B. fragilis | Estrogen-dependent CVD risk (particularly in women); endothelial dysfunction |
| Tryptophanase | Zn, Fe | Metabolizes tryptophan → indole → skatole | Gram-negative Proteobacteria | Shifts indole balance away from protective IPA toward pro-inflammatory indoxyl sulfate |
| Indole production | — | Produces indole (AhR ligand); further metabolized to indoxyl sulfate (pro-inflammatory) | Enterobacteriaceae, Bacteroides | Indoxyl sulfate accumulation; vascular inflammation; endothelial dysfunction |
Interkingdom Relationships
Fungal-bacterial biofilms have not been extensively studied in CVD, but periodontal biofilms are well-characterized foroughi 2026 periodontal biomarkers cvd. Candida albicans is a frequent oral co-isolate with P. gingivalis in periodontitis and may enhance:
- Biofilm biomass and stability
- Bacterial adhesion to host tissues
- Enhanced resistance to antimicrobial peptides
In the gut, biofilm formation by TMAO-producing E. coli and B. fragilis may:
- Create local microanaerobic pockets → select for strict anaerobes
- Shield pathogens from host immune attack
- Facilitate rapid diffusion of LPS and TMAO metabolites across epithelial layers
Ecological State
The CVD microbiome exhibits several hallmark ecological features:
Hypoxia and Oxygen Gradients
- Obligate anaerobes predominate (Bacteroides fragilis, Prevotella, Porphyromonas) — indicating reduced intestinal oxygen penetration, likely due to:
- Loss of mucosal blood flow (from endothelial dysfunction and atherosclerosis)
- Increased bacterial oxygen consumption (NiFe-hydrogenase in E. coli)
- Disrupted intestinal motility (common in CVD)
- Hypoxia selects against oxygen-sensitive commensals and favors obligate anaerobes (Primitive 9)
TMAO-Dominant Metabolite Ecosystem
- TMA lyase genes (CutC/D) are functionally enriched in ACVD metagenomes jie 2017 gut microbiome acvd; these represent the dominant metabolic strategy in the ACVD dysbiosis
- TMAO production is escalation feature in progression from metabolic syndrome → dysmetabolism → IHD fromentin 2022 microbiome metabolome cardiometabolic spectrum
- TMAO-producing taxa competitively exclude SCFA-producing taxa by outgrowing them under iron-rich conditions
Butyrate Depletion Ecosystem
- SCFA production (especially butyrate, measured as molecular functional module MF0089) is depleted at dysmetabolism stage and remains depleted in IHD fromentin 2022 microbiome metabolome cardiometabolic spectrum
- Loss of butyrate ecosystem has two consequences:
1. Gut barrier failure — tight junctions not maintained → increased intestinal permeability
2. No SCFA-mediated BP regulation — loss of Olfr78/FFAR3 signaling → uncontrolled hypertension and worsening heart failure
Indoxyl Sulfate Accumulation Pathway
- Indoxyl sulfate is an escalation feature in the dysmetabolism→IHD progression fromentin 2022 microbiome metabolome cardiometabolic spectrum
- Accumulates via:
1. Tryptophan deamination by dysbiotic taxa (particularly Proteobacteria)
2. Host-mediated sulfation and hepatic recirculation
3. Impaired renal clearance (especially in comorbid CKD)
- Indoxyl sulfate drives vascular inflammation via:
- Endothelial dysfunction (inhibits eNOS)
- Oxidative stress (ROS generation)
- Coagulation activation
LPS-Driven Endotoxemia
- Lipopolysaccharide (LPS) from gram-negative Enterobacteriaceae and Bacteroides translocates across the disrupted gut barrier
- Systemic LPS activates TLR4 on endothelial cells, macrophages, and platelets:
- Upregulation of adhesion molecules (ICAM-1, VCAM-1)
- Leukocyte infiltration → atherosclerotic plaque formation
- Macrophage foam cell formation
- Platelet activation → thrombotic risk
- LPS also activates NLRP3 inflammasome in monocytes/macrophages → IL-1-beta and IL-18 release → vascular inflammation
Multi-Site Dysbiosis: Oral-to-Gut Axis
- Oral dysbiosis (periodontitis) precedes or accompanies gut dysbiosis tonelli 2023 oral microbiome cvd pathophysiology, foroughi 2026 periodontal biomarkers cvd
- Periodontal pathogens seed systemic circulation: P. gingivalis, VGS, and Streptococcus aureus bacteremia detected via:
- Bacterial DNA in atherosclerotic plaques
- Antibodies to P. gingivalis in CVD patients
- FISH-detected bacteria in endothelial lesions
- Oral-derived pathogenic signals compound gut dysbiosis via:
- Systemic inflammation (IL-6, TNF-alpha, CRP elevation)
- Molecular mimicry (HSP60 cross-reactivity)
- Endothelial permeability increase → facilitating gut-derived LPS translocation
Validated Interventions
[To be populated by Cureva team with triangle-validated interventions linking signature features to clinical outcomes]
STOPs
[To be populated by Cureva team with evidence-based counterproductive interventions]
Open Questions
1. Causal primacy of metals vs. dysbiosis: Does metal exposure initiate dysbiosis, or does dysbiosis increase metal bioavailability? Likely bidirectional.
2. Metal accumulation kinetics in CVD: Do metal levels rise progressively, or reach a threshold that triggers ecological collapse? Longitudinal biomonitoring studies needed.
3. Oral-gut dysbiosis timing: Does periodontitis precede gut dysbiosis in CVD development, or are they concurrent manifestations? Prospective cohort studies required.
4. Functional role of fungal mycobiota in CVD: The mycobiome (fungal microbiota) is largely unstudied in CVD; does Candida or other fungi participate in CVD-associated biofilms?
5. Intervention optimization: Which combination of metal reduction (dietary), SCFA restoration (prebiotics/probiotics), and pathogen suppression (antibiotics, antimicrobial botanicals) is most effective? Clinical trials needed.
6. Role of sex hormones in CVD-microbiome axis: Beta-glucuronidase activity enables estrogen recirculation; does estrogen-dependent CVD risk in women reflect dysbiosis-driven estrobolome dysregulation? Mechanistic studies needed.
7. Selenium supplementation in CVD: Is selenium depletion primary (driving dysbiosis) or secondary (due to increased consumption by dysbiotic taxa)? Does supplementation restore glutathione peroxidase activity?
Knowledge Primitives Applied
1. Metals as Selective Pressures (Primitive 1) — Elevated nickel, lead, cadmium, and iron select for tolerant Enterobacteriaceae while eliminating metal-sensitive commensals (Roseburia, Faecalibacterium, Clostridium).
2. Nutritional Immunity as Interpretive Constraint (Primitive 2) — Elevated hepcidin and lipocalin-2 indicate functional anemia and iron sequestration as host defense, not nutritional deficiency. Iron supplementation would feed TMAO-producing pathogens.
3. Mis-metallation and Toxic Metal Entry (Primitive 3) — Lead and cadmium displace correct cofactors (Zn, Mg) via calcium channels, directly impairing cardiomyocyte function and endothelial defense.
4. Microbial Metal Dependencies as Achilles' Heels (Primitive 4) — TMAO-producing Enterobacteriaceae depend on TMA lyase (Fe, Ni cofactors), siderophore iron piracy (Fe), and LPS biosynthesis (Zn, Fe, Mn). Restricting these metals would disable the primary pathogenic pathway.
5. Two-Sided Ecological Engineering (Primitive 5) — CVD intervention requires both suppression of TMAO-producing/LPS-generating pathogens AND restoration of SCFA-producing (Roseburia, Faecalibacterium) and indole-producing (Clostridium) taxa.
6. Interkingdom Relationships and Functional Shielding (Primitive 6) — Periodontal biofilms (fungal-bacterial) and gut biofilms (pathogenic bacterial consortia) protect pathogens from immune attack and antimicrobial compounds.
7. Estrobolome and Hormone Recirculation (Primitive 7) — Beta-glucuronidase activity by dysbiotic E. coli and Streptococcus enables estrogen deconjugation and hepatic recirculation, potentially explaining sex-dependent CVD-microbiome associations.
8. Siderophore Competition and Iron Ecology (Primitive 8) — Enterobacteriaceae outcompete SCFA producers via superior iron acquisition systems (enterobactin, yersiniabactin), establishing TMAO dominance in iron-enriched environments.
9. Oxygen State as Ecological Determinant (Primitive 9) — Hypoxia-driven obligate anaerobe enrichment selects against aerobic commensals and favors Bacteroides fragilis and Porphyromonas gingivalis, amplifying LPS-driven pathology.
---
References Summary
This signature integrates evidence from 64 peer-reviewed sources spanning:
- Landmark metagenomics: jie 2017 gut microbiome acvd (218 ACVD vs. 187 controls; TMA lyase enrichment)
- Mechanistic TMAO pathway: zhen 2023 tmao cardiovascular diseases review (comprehensive review of TMAO biosynthesis, atherosclerosis, HF, HTN mechanisms)
- Multi-omic integration: fromentin 2022 microbiome metabolome cardiometabolic spectrum (MetaCardis cohort; dysmetabolism→IHD trajectory; escalation/de-escalation features)
- Metabolite-specific causal evidence: luo 2022 gut microbiota metabolites heart failure mr (Mendelian randomization; betaine, tryptophan, TMAO, phenylalanine HF risk)
- Bidirectional causality: li 2023 gut microbiome hypertension bidirectional mr (MR; 13 taxa causal for hypertension; hypertension itself worsens dysbiosis)
- Oral-CVD axis: tonelli 2023 oral microbiome cvd pathophysiology, foroughi 2026 periodontal biomarkers cvd (periodontitis pathogen transmission; HSP60 molecular mimicry; biomarker catalog)
- Tryptophan metabolite pathway: paeslack 2022 tryptophan metabolites vascular inflammation cvd (indole metabolites, AhR signaling, indoxyl sulfate vascular inflammation)
- SCFA cardioprotection: chambers 2018 scfa metabolic cardiovascular health (butyrate BP regulation; gut barrier maintenance)
- Metal-specific CVD evidence: liu 2025 cardiometabolic nickel (nickel epidemiology; animal cardiac toxicity; metal interactions)
- Population-level profiling: walker 2021 framingham gut microbiome cardiometabolic (Framingham Heart Study; microbial diversity loss with CVD risk)
- Intervention landscape: hoffelner 2025 emerging therapy targets microbiome cvd (probiotics, prebiotics, antibiotics for microbiome-CVD targets)
- Comprehensive review: herrema 2020 microbiome cardiovascular disease ascvd (gut/oral microbiome, TMAO, imidazole-propionate, SCFAs, bile acids, bacteriophages)